Page last updated: 2024-08-17

bromodeoxyuridine and Day Blindness

bromodeoxyuridine has been researched along with Day Blindness in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Cai, L; Forrester, JV; Jackson, IJ; Lang, B; McCaig, CD; McKie, L; Shen, S; Zhao, L	1

Other Studies

1 other study(ies) available for bromodeoxyuridine and Day Blindness

Article	Year
GABAergic amacrine cells and visual function are reduced in PAC1 transgenic mice. Neuropharmacology, 2010, Volume: 58, Issue:1 Topics: Amacrine Cells; Animals; Animals, Newborn; Bromodeoxyuridine; Cell Death; Cyclin-Dependent Kinase Inhibitor p57; gamma-Aminobutyric Acid; In Situ Nick-End Labeling; Ki-67 Antigen; Mice; Mice, Inbred C57BL; Mice, Transgenic; Nerve Tissue Proteins; Nystagmus, Optokinetic; Pituitary Adenylate Cyclase-Activating Polypeptide; Receptors, Pituitary Adenylate Cyclase-Activating Polypeptide, Type I; Retina; Transcription Factor Brn-3A; Vision Disorders; Visual Acuity	2010

Article

Year

GABAergic amacrine cells and visual function are reduced in PAC1 transgenic mice.

Neuropharmacology, 2010, Volume: 58, Issue:1

Topics: Amacrine Cells; Animals; Animals, Newborn; Bromodeoxyuridine; Cell Death; Cyclin-Dependent Kinase Inhibitor p57; gamma-Aminobutyric Acid; In Situ Nick-End Labeling; Ki-67 Antigen; Mice; Mice, Inbred C57BL; Mice, Transgenic; Nerve Tissue Proteins; Nystagmus, Optokinetic; Pituitary Adenylate Cyclase-Activating Polypeptide; Receptors, Pituitary Adenylate Cyclase-Activating Polypeptide, Type I; Retina; Transcription Factor Brn-3A; Vision Disorders; Visual Acuity

2010